Alira Health

Alira Health

EADV Congress 2022

September 7-10, 2022 | Milan & Online

We are pleased to share that our team will be attending EADV Congress 2022 in Milan this September. EADV Congress is an outstanding educational and learning experience for dermatologists and venereologists world-wide, and our team will be pleased to join it alongside our partner Legit.Health.

Alira Health and Legit.Health will be attending EADV Congress 2022 following the roll-out of the unique next generation technology solution for dermatology DCT, RWE and DTx. This joint solution is designed to automate the verification of inclusion criteria, automate participant monitoring and clinical endpoint acquisition and recruitment, and increase the diversity of participants. Learn more about the solution from the partnership announcement.

Our delegates
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access & Pricing, Alira Health
Kumara Prasad Palanivel

Dr. Kumara Prasad Palanivel

Director, Digital Medical Strategy, Alira Health

Would you like to meet at EADV and learn more about our unique platform for dermatology DCT, RWE and DTx?

Related news

News May 6, 2024
Alira Health’s CDD Advises TVM Capital Healthcare Investment in neurocare Group AG
We are pleased to have been a Commercial Due Diligence advisor for an investment by TVM Capital Healthcare into neurocare group AG. The Munich-based leader in personalized mental health(...)
CDD Digital Therapeutics
Reports April 17, 2024
LENMELDY Approval by FDA Relied on RWE
The FDA recently approved LENMELDY® (atidarsagene autotemcel), a gene therapy indicated for the treatment of metachromatic leukodystrophy (MLD), a rare disease, based on RWE.
Real-World Evidence (RWE) RWE Decision Alert
Reports April 11, 2024
The Spanish AEMPS Approves EBVALLO, Supported by Effectiveness and Safety Data from RWE
On February 8, 2024, the Spanish Agency for Medicines (AEMPS) approved EBVALLO® (tabelecleucel) for the treatment of lymphoproliferative disorders, leveraging effectiveness and safety(...)
Real-World Evidence (RWE) RWE Decision Alert
Events March 27, 2024
ISPOR 2024
We are excited to announce that we will attend and present posters at ISPOR 2024, the leading global conference for HEOR.
HEOR Lupus Real-World Evidence (RWE)
News March 27, 2024
Alira Health Joins Forces with APMA to Advance Podiatric Registry
Alira Health joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and(...)
Real-World Evidence (RWE) Registry-based studies Research and Development Wound Healing
Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
Reports February 15, 2024
FDA Approves GAMMAGARD LIQUID Based on Safety Data From an RWE Study
Food and Drug Administration (FDA) approves GAMMAGARD LIQUID based on safety data from a real-world evidence study.
Real-World Evidence (RWE) RWE Decision Alert
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.